Abstract
Background and purpose — Few prospective studies have reported the long-term effect durability of collagenase injections for Dupuytren disease. We assessed the 3-year treatment outcome of collagenase injections and predictors of recurrence.Patients and methods — We conducted a single-center prospective cohort study. Indication for collagenase injection was palpable Dupuytren’s cord and active extension deficit (AED) ≥ 20° in the metacarpophalangeal (MCP) and/or proximal interphalangeal (PIP) joint. From November 2012 through June 2013, we treated 86 consecutive patients (92 hands, 126 fingers). A hand therapist measured joint contracture before, 5 weeks, and 3 years after injection. The patients rated their treatment satisfaction. Primary outcome was proportion of treated joints with ≥ 20° AED worsening between the 5-week and 3-year measurements. We analyzed predictors of recurrence.Results — 3-year outcomes were available for 83 of the 86 patients (89 hands, 120 treated fingers). Between the 5-week and 3-year measurements, AED worsened by ≥ 20° in 17 MCP (14%) and 28 PIP (23%) joints. At 3 years, complete correction (passive extension deficit 0–5°) was present in 73% of MCP and 35% of PIP joints. Treatment of small finger PIP joint contracture, greater pretreatment contracture severity, and previous fasciectomy on the treated finger were statistically significant predictors of recurrence. Treatment satisfaction was rated as very satisfied or satisfied in 59 of 87 hands. No long-term treatment-related adverse events were observed.Interpretation — 3 years after collagenase injections for Dupuytren disease, improvement was maintained and treatment satisfaction reported in two-thirds of the treated hands, with no adverse events. Complete contracture correction was achieved in 3 of 4 MCP joints, but in only a third of the PIP joints.
Highlights
3-year outcomes were available for 83 of the 86 patients (89 hands, 120 treated fingers)
No patient suffered from neurovascular injury, flexor tendon injury, infection, or complex regional pain syndrome during the study period. This prospective cohort study of consecutive patients with Dupuytren disease treated with collagenase injection using a modified injection method, with near complete follow-up, has shown that improvement was maintained in two-thirds of the treated hands 3 years after treatment
Previous studies have shown that proximal interphalangeal (PIP) joints have a higher recurrence rate regardless of treatment method
Summary
3-year outcomes were available for 83 of the 86 patients (89 hands, 120 treated fingers). At 3 years, complete correction (passive extension deficit 0–5°) was present in 73% of MCP and 35% of PIP joints. Interpretation — 3 years after collagenase injections for Dupuytren disease, improvement was maintained and treatment satisfaction reported in two-thirds of the treated hands, with no adverse events. Collagenase injection and percutaneous needle fasciotomy are established first-line treatment options (van Rijssen et al 2012, Peimer et al 2015). Advantages of these minimally invasive procedures compared with fasciectomy are safety (Krefter et al 2017), quick recovery and lower cost (Atroshi et al 2014). In the present study we assess 3-year treatment outcomes of collagenase injections using the modified injection technique, including assessment of predictors of recurrence and patient dissatisfaction
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
